ASMDC not checked

Innovacell GmbH

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Autologous Muscle Derived Cells for injection into the external anal sphincter”In the company’s words, NCT04976153 on ClinicalTrials.gov
Tested for
Fecal Incontinence
Main trialPhase 3
“The objective of this study is the final assessment of clinical safety and efficacy of autologous autologous skeletal muscle derived cells for patients with urge fecal incontinence due to external anal sphincter dysfunction caused by its disruption and/or weakness.”In the company’s words, NCT04976153 on ClinicalTrials.gov

Other drugs for Fecal Incontinence

All 3 drugs for Fecal Incontinence

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2027 Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ASMDC

Following is part of Solo: you see every change to ASMDC the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in